To evaluate whether CD99-targeted irinotecan nanoparticles (NV103) could overcome resistance in relapsed Ewing sarcoma, we used CHLA-10, a cell line derived from a patient whose tumor progressed despite standard 5-agent VAC/IE chemotherapy. Here, CD99 is linked to neoplasm.